Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer.

Kim, Jin-Chul; Heo, You-Jeong; Kang, So-Young; Lee, Jeeyun; Kim, Kyoung-Mee

Kim, Jin-Chul; Heo, You-Jeong; Kang, So-Young; Lee, Jeeyun; Kim, Kyoung-Mee.

Afiliação

Kim JC; Samsung Medical Center, Department of Medicine, Division of Hematology-Oncology, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Heo YJ; Samsung Medical Center, The Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Kang SY; Samsung Medical Center, Department of Pathology and Translational Genomics, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Lee J; Samsung Medical Center, Department of Medicine, Division of Hematology-Oncology, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Kim KM; Samsung Medical Center, Department of Pathology and Translational Genomics, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.

Cancers (Basel) ; 13(10)2021 May 12.

Article em En | MEDLINE | ID: mdl-34065963

Palavras-chave

PD-L1; biomarker; cancer; immune checkpoint inhibitors; prediction

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google